SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (293)8/29/2002 8:37:40 AM
From: quidditch   of 508
 
Results at CHEST will be very interesting to dissect, trying to unravel the seeming contradiction between FVC and mortality benefit. I assume that the November meeting will address only the P3 trial results as disclosed preliminarily yesterday, and not the follow-on information for the open label continuation.

I would guess that price will retreat some as those in for a ST pop close their positions--shorts emboldened by WSJ piece. If ITMN does not get munched beforehand, it will be interesting to see how actimmune sales increase, together with results of oritavancin trials. I was impressed by the emphasis, during presentation at the NYC analysts conference in July, of oritavancin's dual mode of action--in theory making it less susceptible to development of resistance. Not a one-trick pony.

quid
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News